sodium deoxycholate / Generic mfg. - LARVOL DELTA

Comparison of Cholic Acid (MT921) and Deoxycholic Acid (DCA) in Fat Reduction Efficacy and Skin Adverse Reactions in Mini Pigs and Rodent Models. (PubMed, Pharmaceuticals (Basel)) - "DCA is the active pharmaceutical ingredient found in several fat-dissolving injectables, such as Kybella®, V-OLET®, and Bellacholine®. Notably, MT921 evoked milder ADR based on lower incidence of hematoma and absence of nodules in mini pigs, less severe UD in mice, and reduced edema in rats. Local injections of 1.5% MT921 demonstrated fat-reduction efficacy comparable to 1% DCA while eliciting fewer and milder ADRs, supporting MT921 as a promising alternative lipolytic agent."

Journal • Preclinical • Dermatitis • Dermatology • Fibrosis • Immunology • Obesity

Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas (clinicaltrials.gov) - P1 | N=13 | Completed | Sponsor: Massachusetts General Hospital | Recruiting ➔ Completed | N=30 ➔ 13 | Trial completion date: Oct 2024 ➔ Jul 2025 | Trial primary completion date: Oct 2024 ➔ Jul 2025

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Genetic Disorders • Neurofibromatosis • Pain • Solid Tumor

Assessing the Efficacy of Repeat, Monthly Treatments of Deoxycholate for NF1 Associated Cutaneous Neurofibromas (cNFs) (clinicaltrials.gov) - P1 | N=15 | Enrolling by invitation | Sponsor: Massachusetts General Hospital | Not yet recruiting ➔ Enrolling by invitation | N=10 ➔ 15

Enrollment change • Enrollment open • Genetic Disorders • Neurofibromatosis • Solid Tumor

Intralesional Ronkyla Plus Injection for the Treatment of Superficial Lipoma (clinicaltrials.gov) - P1 | N=56 | Recruiting | Sponsor: Glonova Pharma Co., Ltd

New P1 trial

NBT-QYDS-002: Randomized, blind, parallel, and positive-controlled Phase I clinical trials of subcutaneous fat layer injection treatment in people with excess subcutaneous fat accumulation in Chinese jaws (ChiCTR) - P1 | N=40 | Not yet recruiting | Sponsor: Peking Union Medical College Hospital; Peking Union Medical College Hospital

New P1 trial

US Harmony: A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (clinicaltrials.gov) - P4 | N=130 | Recruiting | Sponsor: AbbVie | N=100 ➔ 130 | Trial primary completion date: Jul 2026 ➔ Mar 2026

Enrollment change • Trial primary completion date

Minimally Invasive Treatments in Patients Presenting for Rhytidectomy: A Patient Reported Survey of Incidence and Satisfaction (PSTM 2025) - "Reported MITs included fillers (n=13), laser (n=10), energy-based treatments (n=9), chemical peel (n=8), microneedling (n=5), and Kybella or cool-sculpting (n=1), with significant variation in treatment type distribution (p=0.02)... Patients seeking rhytidectomy or platysmaplasty are significantly more likely to have undergone MITs, with female patients particularly likely to report prior treatments. Variability in the likelihood of intervention choice suggests certain modalities are more popular. Fillers and peel/laser treatments were associated with higher satisfaction and improvement compared to energy-based therapies, which had lower repeat rates."

Clinical • Aesthetic Medicine

Neck Lift After Nonsurgical Treatments: Fibrosis, Fat Loss, and Surgical Complexity. (PubMed, Aesthet Surg J) - "Noninvasive neck treatments significantly alter tissue architecture, increasing surgical complexity and impacting aesthetic outcomes. Surgeons should anticipate these challenges, modify techniques accordingly, and emphasize thorough preoperative evaluation and patient counseling to anticipate increased risk and optimize results."

Journal • Aesthetic Medicine • Fibrosis • Immunology

Comparison of Patient Reviews for Submental Liposuction and Kybella Using Deep Learning and Natural Language Processing: Is There a Superior Intervention for Submental Adiposity? (PubMed, Aesthet Surg J) - "This study applied NLP to extract structured sentiment from unstructured reviews RealSelf. Our findings suggest that submental liposuction patients report greater satisfaction and more positive emotional experiences than those who received Kybella."

Journal • Aesthetic Medicine • Obesity

Cryolipolysis Versus ATX-101 (Deoxycholic Acid) for Upper Back Fat (clinicaltrials.gov) - P=N/A | N=8 | Terminated | Sponsor: Northwestern University | N=34 ➔ 8 | Active, not recruiting ➔ Terminated; Unable to enroll participants for analysis.

Enrollment change • Trial termination • Aesthetic Medicine

A Phase I Study of HY-2003 in the Subjects With Excessive Submental Fat Accumulation (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd | Not yet recruiting ➔ Recruiting

Enrollment open

Selecting the Right Technique for the Treatment of Submental Adiposity. (PubMed, Facial Plast Surg) - "Percutaneous treatments include Kybella or enzymatic mixture injection and transcutaneous energy delivery. Liposuction with or without adjunctive treatments and deep neck lifts are the subcutaneous and structural options.Submental interventions, whether percutaneous, transcutaneous, or subcutaneous, amplify the natural characteristics and beauty of the patient. Aligning the proper technique with the proper patient is the mark of a perceptive surgeon who accounts for underlying anatomy and treatment goals."

Journal • Aesthetic Medicine • Infectious Disease • Obesity

Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas (clinicaltrials.gov) - P1 | N=34 | Completed | Sponsor: Massachusetts General Hospital | Active, not recruiting ➔ Completed | N=20 ➔ 34 | Trial completion date: Dec 2024 ➔ Apr 2024 | Trial primary completion date: Dec 2024 ➔ Apr 2024

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Genetic Disorders • Neurofibromatosis • Solid Tumor

Dosing and Tolerability of Deoxycholic Acid Vs. Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas (clinicaltrials.gov) - P1 | N=20 | Completed | Sponsor: Massachusetts General Hospital | Recruiting ➔ Completed | Trial completion date: Sep 2024 ➔ Jan 2025 | Trial primary completion date: Apr 2024 ➔ Jan 2025

Trial completion • Trial completion date • Trial primary completion date • Genetic Disorders • Neurofibromatosis • Solid Tumor • NF1

US Harmony: A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (clinicaltrials.gov) - P4 | N=100 | Recruiting | Sponsor: AbbVie

New P4 trial

A Phase I Study of HY-2003 in the Subjects With Excessive Submental Fat Accumulation (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd

New P1 trial

Accessory Axillary Breast Management: Is Primary Skin Excision Necessary? (PubMed, Indian J Plast Surg) - "While modalities like CoolScupting™, Kybella™ injections, and BodyTite™ have been used by surgeons for management of axillary breasts, the most effective treatment for this condition remains surgical management involving a combination of liposuction of the axillary breast with excision of the gland and skin...Any skin excess is best dealt with secondarily. The author uses a modified protocol without any primary skin excision in axillary breast management to achieve excellent results with minimal scars."

Journal • Aesthetic Medicine

Aesthetic Facial Surgery: a Systematic Review. (PubMed, Clin Ter) - "In order to do this, common nonsurgical treatments including threaded processes, Botox injections Kybella, filler substances, micro-focused ultrasound, and pharmacologic hair transplantation will be examined in contrast to common surgical treatments like face lifts, blepharoplasty, rhinoplasty procedure and transplantation of hair. This study examines the latest advancements and patterns in medical practitioners' methods to bolster the expansion of cosmetic face surgery in India. It also seeks to solve the inadequacies in the current administration and close the gaps that can be found in the realm of cosmetic surgery."

Journal • Review • Surgery • Aesthetic Medicine • Pain • Transplantation

Deoxycholic Acid for Submental Convexity: A MAUDE Database Analysis. (PubMed, Craniomaxillofac Trauma Reconstr) - "The MAUDE database was queried for all reports related to adverse events involving deoxycholic acid using the search terms "KYBELLA" and "deoxycholic acid." Reports were individually reviewed by 2 reviewers and categorized with special attention to adverse events...Adverse events following DOC injections included excessive swelling, dysphagia, numbness, infection, unsatisfactory aesthetic outcome, facial nerve weakness, and skin necrosis requiring hospitalization and/or surgery. Patient counseling regarding these adverse events should be discussed when offering DOC injections for submental convexity."

Journal • Aesthetic Medicine • Gastrointestinal Disorder • Infectious Disease

Assessing the Efficacy of Repeat, Monthly Treatments of Cutaneous Neurofibromas (cNFs) (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: Massachusetts General Hospital

New P1 trial • Fibrosis • Genetic Disorders • Neurofibromatosis • Solid Tumor

Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Massachusetts General Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Fibrosis • Genetic Disorders • Neurofibromatosis • Pain • Solid Tumor

Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Massachusetts General Hospital

New P1 trial • Fibrosis • Genetic Disorders • Neurofibromatosis • Pain • Solid Tumor

Dosing and Tolerability of Deoxycholic Acid Versus Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: Massachusetts General Hospital

New P1 trial • Fibrosis • Genetic Disorders • Neurofibromatosis • Solid Tumor • NF1

Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas (clinicaltrials.gov) - P1 | N=20 | Active, not recruiting | Sponsor: Massachusetts General Hospital | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Jun 2023 ➔ Dec 2024

Enrollment closed • Trial completion date • Trial primary completion date • Fibrosis • Genetic Disorders • Neurofibromatosis • Solid Tumor

Degradation Therapy with Collagenase and Deoxycholate. (PubMed, Facial Plast Surg Clin North Am) - "This article will discuss the indications for the use of deoxycholic acid, primarily its well-established role in the non-surgical reduction of submental fat, with a focus on patient assessment, procedural technique, risks, pitfalls, and key clinical tips. It will also review the indications for collagenase as a degradation therapy, its mechanism of action, and benefits in the management of wound healing, scarring, and adipose tissue modification."

Journal • Review